Skip to main content

Table 2 Safety and reported adverse events, occurring in two or more subjects, which were possibly, probably or definitely related to DPX-0907 treatment

From: First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

Toxicity Total No. of Patients 0.25 mL Group 1 mL Group
  0.25 mL 1 mL Grade 1 Grade 2 Grade 1 Grade 2 Grade 3
Injection site induration 11 9 6 5 3 5 1
Injection site erythema 8 10 6 2 5 4 1
Injection site pain 3 8 1 2 3 5  
Injection site pruritis 3 2 3   1 1  
Injection site warmth 2 2 1 1 1 1  
Injection site hematoma 2   2     
Injection site edema 1 4 1   2 2  
Injection site discoloration 1 2   1 2   
Injection site rash 1 1 1    1  
Injection site urticaria 1 1 1    1  
Injection site dry skin 1 1 1   1   
Injection site ulceration   3    1   2*
Pain 3 1 2 1   1  
Fatigue 2   1 1    
Fever 1 2   1 1 1  
Arthralgia 1 1 1   1   
Myalgia 1 1 1   1   
Anaemia 1 1   1   1  
  1. *Appeared three or more weeks after of third injection and completely resolved.